Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals
Since 1991, new epidemic methicillin-resistant Staphylococcus aureus (MRSA) strains characterized by the unexpected reappearance of heterogeneous phenotypic expression of resistance to methicillin and by susceptibility to gentamicin and various other antibiotics (GS-MRSA) have been reported in Franc...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2001-03, Vol.47 (3), p.277-283 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 283 |
|---|---|
| container_issue | 3 |
| container_start_page | 277 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 47 |
| creator | Laurent, Frédéric Lelièvre, Hervé Cornu, Marie Vandenesch, François Carret, Gérard Etienne, Jerome Flandrois, Jean-Pierre |
| description | Since 1991, new epidemic methicillin-resistant Staphylococcus aureus (MRSA) strains characterized by the unexpected reappearance of heterogeneous phenotypic expression of resistance to methicillin and by susceptibility to gentamicin and various other antibiotics (GS-MRSA) have been reported in France. GS-MRSA strains have progressively replaced MRSA clones expressing homogeneous resistance to methicillin and resistance to gentamicin (GR-MRSA). In this study, we investigated the physiological characteristics of these new clones. In particular, we evaluated and compared the maximal growth rate and the deduced generation times (related to fitness of strains) of the major French epidemic MRSA clones. The population studied consisted of 79 isolates including (i) GR-MRSA that comprised six different types on the basis of PFGE; (ii) GS-MRSA the majority of which clustered into two PFGE types, A1 (usually resistant to erythromycin) and B (usually susceptible to erythromycin); (iii) methicillin-susceptible S. aureus (MSSA). GS-MRSA-A1 and MSSA strains were shown to have a significant fitness benefit (about 20%) with shorter generation times (θ = 23.7 ± 0.1 and 22.9 ± 0.05 min, respectively) than GR-MRSA and GS-MRSA-B strains (θ = 30.3 ± 0.2 and 32.5 ± 0.5 min, respectively). These data suggest that a link exists between genetic patterns, resistance profiles and physiological properties. In vitro competitive experiments indicated that GS-MRSA- A1 strains were able to rapidly outgrow GR-MRSA strains. The growth advantage observed should be taken into account in understanding the spread of some new clones of MRSA. |
| doi_str_mv | 10.1093/jac/47.3.277 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02332592v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>376649261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-1d262841ea04a0da660f7f670d375d80ff297e650cd767363d52483df417d673</originalsourceid><addsrcrecordid>eNqFkd2LEzEUxYMobrf65rMEBUFwuvnOzGNZrBUqsmuRxZeQTTJt6kxmTGa6639vSksFX3y63JvfPeTcA8ArjGYYVfRqp80VkzM6I1I-ARPMBCoIqvBTMEEU8UIyTi_AZUo7hJDgonwOLjAmhHCBJqBf-CG4lKAOFpqu7d3gB793cBO7h2ELtd3rMOiNg10Ng3uAG5fb1hsfijQm4_rB3zcOfrn9Noem6bIWTH102vqwgT7ARXTBbOG2S70fdJNegGd1Lu7lqU7BevFxfb0sVl8_fb6erwrDSjoU2BJBSoadRkwjq4VAtayFRJZKbktU16SSTnBkrBSSCmo5yYu2ZljaPJiC90fZrW5UH32r42_Vaa-W85U6zBChlPCK7HFm3x3ZPna_RpcG1frsrGl0cN2YlESCyiqr_w_EJSsxz_eegjf_gLtujCH7VQRLITgRIkMfjpCJXUrR1ed_YqQO0aocrWJSUZWjzfjrk-Z43zr7Fz5lmYG3J0Ano5s66mB8OnMVZkwcPBRHyqfBPZ5fdfyp8tkkV8u7Hwrfrb_fVDe3StA_wfe5ow</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217665266</pqid></control><display><type>article</type><title>Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Free Full-Text Journals in Chemistry</source><creator>Laurent, Frédéric ; Lelièvre, Hervé ; Cornu, Marie ; Vandenesch, François ; Carret, Gérard ; Etienne, Jerome ; Flandrois, Jean-Pierre</creator><creatorcontrib>Laurent, Frédéric ; Lelièvre, Hervé ; Cornu, Marie ; Vandenesch, François ; Carret, Gérard ; Etienne, Jerome ; Flandrois, Jean-Pierre</creatorcontrib><description>Since 1991, new epidemic methicillin-resistant Staphylococcus aureus (MRSA) strains characterized by the unexpected reappearance of heterogeneous phenotypic expression of resistance to methicillin and by susceptibility to gentamicin and various other antibiotics (GS-MRSA) have been reported in France. GS-MRSA strains have progressively replaced MRSA clones expressing homogeneous resistance to methicillin and resistance to gentamicin (GR-MRSA). In this study, we investigated the physiological characteristics of these new clones. In particular, we evaluated and compared the maximal growth rate and the deduced generation times (related to fitness of strains) of the major French epidemic MRSA clones. The population studied consisted of 79 isolates including (i) GR-MRSA that comprised six different types on the basis of PFGE; (ii) GS-MRSA the majority of which clustered into two PFGE types, A1 (usually resistant to erythromycin) and B (usually susceptible to erythromycin); (iii) methicillin-susceptible S. aureus (MSSA). GS-MRSA-A1 and MSSA strains were shown to have a significant fitness benefit (about 20%) with shorter generation times (θ = 23.7 ± 0.1 and 22.9 ± 0.05 min, respectively) than GR-MRSA and GS-MRSA-B strains (θ = 30.3 ± 0.2 and 32.5 ± 0.5 min, respectively). These data suggest that a link exists between genetic patterns, resistance profiles and physiological properties. In vitro competitive experiments indicated that GS-MRSA- A1 strains were able to rapidly outgrow GR-MRSA strains. The growth advantage observed should be taken into account in understanding the spread of some new clones of MRSA.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/47.3.277</identifier><identifier>PMID: 11222560</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Analysis. Health state ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Bacteriology ; Biodiversity ; Biological and medical sciences ; Cell Division - drug effects ; DNA, Bacterial - genetics ; Drug Resistance, Microbial ; Drug Resistance, Multiple ; Ecology, environment ; Ecosystems ; Electrophoresis, Gel, Pulsed-Field ; Epidemiology ; France ; General aspects ; Gentamicins - pharmacology ; Hospitals ; Human bacterial diseases ; Humans ; Infectious diseases ; Kinetics ; Life Sciences ; Medical sciences ; Methicillin Resistance ; Microbial Sensitivity Tests ; Microbiology and Parasitology ; Pharmacology. Drug treatments ; Populations and Evolution ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Quantitative Methods ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - genetics ; Staphylococcus aureus - growth & development ; Systematics, Phylogenetics and taxonomy ; Time Factors</subject><ispartof>Journal of antimicrobial chemotherapy, 2001-03, Vol.47 (3), p.277-283</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Mar 2001</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-1d262841ea04a0da660f7f670d375d80ff297e650cd767363d52483df417d673</citedby><orcidid>0000-0002-4953-9125</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=914468$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11222560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02332592$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Laurent, Frédéric</creatorcontrib><creatorcontrib>Lelièvre, Hervé</creatorcontrib><creatorcontrib>Cornu, Marie</creatorcontrib><creatorcontrib>Vandenesch, François</creatorcontrib><creatorcontrib>Carret, Gérard</creatorcontrib><creatorcontrib>Etienne, Jerome</creatorcontrib><creatorcontrib>Flandrois, Jean-Pierre</creatorcontrib><title>Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>Since 1991, new epidemic methicillin-resistant Staphylococcus aureus (MRSA) strains characterized by the unexpected reappearance of heterogeneous phenotypic expression of resistance to methicillin and by susceptibility to gentamicin and various other antibiotics (GS-MRSA) have been reported in France. GS-MRSA strains have progressively replaced MRSA clones expressing homogeneous resistance to methicillin and resistance to gentamicin (GR-MRSA). In this study, we investigated the physiological characteristics of these new clones. In particular, we evaluated and compared the maximal growth rate and the deduced generation times (related to fitness of strains) of the major French epidemic MRSA clones. The population studied consisted of 79 isolates including (i) GR-MRSA that comprised six different types on the basis of PFGE; (ii) GS-MRSA the majority of which clustered into two PFGE types, A1 (usually resistant to erythromycin) and B (usually susceptible to erythromycin); (iii) methicillin-susceptible S. aureus (MSSA). GS-MRSA-A1 and MSSA strains were shown to have a significant fitness benefit (about 20%) with shorter generation times (θ = 23.7 ± 0.1 and 22.9 ± 0.05 min, respectively) than GR-MRSA and GS-MRSA-B strains (θ = 30.3 ± 0.2 and 32.5 ± 0.5 min, respectively). These data suggest that a link exists between genetic patterns, resistance profiles and physiological properties. In vitro competitive experiments indicated that GS-MRSA- A1 strains were able to rapidly outgrow GR-MRSA strains. The growth advantage observed should be taken into account in understanding the spread of some new clones of MRSA.</description><subject>Analysis. Health state</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Bacteriology</subject><subject>Biodiversity</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>DNA, Bacterial - genetics</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Resistance, Multiple</subject><subject>Ecology, environment</subject><subject>Ecosystems</subject><subject>Electrophoresis, Gel, Pulsed-Field</subject><subject>Epidemiology</subject><subject>France</subject><subject>General aspects</subject><subject>Gentamicins - pharmacology</subject><subject>Hospitals</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Kinetics</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Methicillin Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiology and Parasitology</subject><subject>Pharmacology. Drug treatments</subject><subject>Populations and Evolution</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Quantitative Methods</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - genetics</subject><subject>Staphylococcus aureus - growth & development</subject><subject>Systematics, Phylogenetics and taxonomy</subject><subject>Time Factors</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd2LEzEUxYMobrf65rMEBUFwuvnOzGNZrBUqsmuRxZeQTTJt6kxmTGa6639vSksFX3y63JvfPeTcA8ArjGYYVfRqp80VkzM6I1I-ARPMBCoIqvBTMEEU8UIyTi_AZUo7hJDgonwOLjAmhHCBJqBf-CG4lKAOFpqu7d3gB793cBO7h2ELtd3rMOiNg10Ng3uAG5fb1hsfijQm4_rB3zcOfrn9Noem6bIWTH102vqwgT7ARXTBbOG2S70fdJNegGd1Lu7lqU7BevFxfb0sVl8_fb6erwrDSjoU2BJBSoadRkwjq4VAtayFRJZKbktU16SSTnBkrBSSCmo5yYu2ZljaPJiC90fZrW5UH32r42_Vaa-W85U6zBChlPCK7HFm3x3ZPna_RpcG1frsrGl0cN2YlESCyiqr_w_EJSsxz_eegjf_gLtujCH7VQRLITgRIkMfjpCJXUrR1ed_YqQO0aocrWJSUZWjzfjrk-Z43zr7Fz5lmYG3J0Ano5s66mB8OnMVZkwcPBRHyqfBPZ5fdfyp8tkkV8u7Hwrfrb_fVDe3StA_wfe5ow</recordid><startdate>20010301</startdate><enddate>20010301</enddate><creator>Laurent, Frédéric</creator><creator>Lelièvre, Hervé</creator><creator>Cornu, Marie</creator><creator>Vandenesch, François</creator><creator>Carret, Gérard</creator><creator>Etienne, Jerome</creator><creator>Flandrois, Jean-Pierre</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><general>Oxford University Press (OUP)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4953-9125</orcidid></search><sort><creationdate>20010301</creationdate><title>Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals</title><author>Laurent, Frédéric ; Lelièvre, Hervé ; Cornu, Marie ; Vandenesch, François ; Carret, Gérard ; Etienne, Jerome ; Flandrois, Jean-Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-1d262841ea04a0da660f7f670d375d80ff297e650cd767363d52483df417d673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Analysis. Health state</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Bacteriology</topic><topic>Biodiversity</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>DNA, Bacterial - genetics</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Resistance, Multiple</topic><topic>Ecology, environment</topic><topic>Ecosystems</topic><topic>Electrophoresis, Gel, Pulsed-Field</topic><topic>Epidemiology</topic><topic>France</topic><topic>General aspects</topic><topic>Gentamicins - pharmacology</topic><topic>Hospitals</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Kinetics</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Methicillin Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiology and Parasitology</topic><topic>Pharmacology. Drug treatments</topic><topic>Populations and Evolution</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Quantitative Methods</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - genetics</topic><topic>Staphylococcus aureus - growth & development</topic><topic>Systematics, Phylogenetics and taxonomy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laurent, Frédéric</creatorcontrib><creatorcontrib>Lelièvre, Hervé</creatorcontrib><creatorcontrib>Cornu, Marie</creatorcontrib><creatorcontrib>Vandenesch, François</creatorcontrib><creatorcontrib>Carret, Gérard</creatorcontrib><creatorcontrib>Etienne, Jerome</creatorcontrib><creatorcontrib>Flandrois, Jean-Pierre</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laurent, Frédéric</au><au>Lelièvre, Hervé</au><au>Cornu, Marie</au><au>Vandenesch, François</au><au>Carret, Gérard</au><au>Etienne, Jerome</au><au>Flandrois, Jean-Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2001-03-01</date><risdate>2001</risdate><volume>47</volume><issue>3</issue><spage>277</spage><epage>283</epage><pages>277-283</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Since 1991, new epidemic methicillin-resistant Staphylococcus aureus (MRSA) strains characterized by the unexpected reappearance of heterogeneous phenotypic expression of resistance to methicillin and by susceptibility to gentamicin and various other antibiotics (GS-MRSA) have been reported in France. GS-MRSA strains have progressively replaced MRSA clones expressing homogeneous resistance to methicillin and resistance to gentamicin (GR-MRSA). In this study, we investigated the physiological characteristics of these new clones. In particular, we evaluated and compared the maximal growth rate and the deduced generation times (related to fitness of strains) of the major French epidemic MRSA clones. The population studied consisted of 79 isolates including (i) GR-MRSA that comprised six different types on the basis of PFGE; (ii) GS-MRSA the majority of which clustered into two PFGE types, A1 (usually resistant to erythromycin) and B (usually susceptible to erythromycin); (iii) methicillin-susceptible S. aureus (MSSA). GS-MRSA-A1 and MSSA strains were shown to have a significant fitness benefit (about 20%) with shorter generation times (θ = 23.7 ± 0.1 and 22.9 ± 0.05 min, respectively) than GR-MRSA and GS-MRSA-B strains (θ = 30.3 ± 0.2 and 32.5 ± 0.5 min, respectively). These data suggest that a link exists between genetic patterns, resistance profiles and physiological properties. In vitro competitive experiments indicated that GS-MRSA- A1 strains were able to rapidly outgrow GR-MRSA strains. The growth advantage observed should be taken into account in understanding the spread of some new clones of MRSA.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>11222560</pmid><doi>10.1093/jac/47.3.277</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4953-9125</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2001-03, Vol.47 (3), p.277-283 |
| issn | 0305-7453 1460-2091 1460-2091 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02332592v1 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Free Full-Text Journals in Chemistry |
| subjects | Analysis. Health state Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Bacteriology Biodiversity Biological and medical sciences Cell Division - drug effects DNA, Bacterial - genetics Drug Resistance, Microbial Drug Resistance, Multiple Ecology, environment Ecosystems Electrophoresis, Gel, Pulsed-Field Epidemiology France General aspects Gentamicins - pharmacology Hospitals Human bacterial diseases Humans Infectious diseases Kinetics Life Sciences Medical sciences Methicillin Resistance Microbial Sensitivity Tests Microbiology and Parasitology Pharmacology. Drug treatments Populations and Evolution Public health. Hygiene Public health. Hygiene-occupational medicine Quantitative Methods Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus aureus - drug effects Staphylococcus aureus - genetics Staphylococcus aureus - growth & development Systematics, Phylogenetics and taxonomy Time Factors |
| title | Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-08T10%3A14%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fitness%20and%20competitive%20growth%20advantage%20of%20new%20gentamicin-susceptible%20MRSA%20clones%20spreading%20in%20French%20hospitals&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Laurent,%20Fre%CC%81de%CC%81ric&rft.date=2001-03-01&rft.volume=47&rft.issue=3&rft.spage=277&rft.epage=283&rft.pages=277-283&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/47.3.277&rft_dat=%3Cproquest_hal_p%3E376649261%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217665266&rft_id=info:pmid/11222560&rfr_iscdi=true |